<DOC>
	<DOC>NCT00396097</DOC>
	<brief_summary>To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment</brief_summary>
	<brief_title>Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Prepubertal children with bone ages between 3 and 10 years of age for males and 3 and 9 years of age for females Naive to Growth Hormone treatment Abnormal karyotype. Small Gestational Age and Skeletal dysplasia.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ISS</keyword>
	<keyword>human growth hormone</keyword>
</DOC>